| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |